JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 23, 2004; DOI: 10.1124/jpet.104.074633


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.074633v1
312/2/441    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Finnegan, T. F
Right arrow Articles by Pan, H.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finnegan, T. F
Right arrow Articles by Pan, H.-L.


Received for publication July 20, 2004.
Revised September 21, 2004.
Accepted for publication September 22, 2004.

Effect of the µ Opioid on Excitatory and Inhibitory Synaptic Inputs to Periaqueductal Gray-Projecting Neurons in the Amygdala

Thomas F Finnegan 1, Shao-Rui Chen 1, Hui-Lin Pan 2*

1 Penn State Univ. 2 Penn State University College of Medicine

* Address correspondence to: E-mail: hpan{at}psu.edu

Abstract

Opioids are potent analgesics but the sites of their action and cellular mechanisms are not fully understood. The central nucleus of the amygdala (CeA) is important for opioid analgesia through the projection to the periaquaductal gray (PAG). In this study, we examined the effects of µopioid receptor stimulation on inhibitory and excitatory synaptic inputs to PAG-projecting CeA neurons retrogradely labeled with a fluorescent tracer injected into the ventrolateral PAG of rats. Whole-cell voltage-clamp recordings were performed on labeled CeA neurons in brain slices. The specific m opioid receptor agonist, [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO, 1 µM), significantly reduced the frequency of mIPSCs without altering the amplitude and decay constant of mIPSCs in 47.6% (10 of 21) of cells tested. DAMGO also significantly decreased the peak amplitude of evoked IPSCs in 69% (9 of 13) of cells examined. However, DAMGO did not significantly alter the frequency of mEPSCs and the amplitude of eEPSCs in 69% (9 of 13) and 83% (10 of 12) of labeled cells, respectively. The IPSCs were blocked by the GABAA receptor antagonist bicuculline, while the EPSCs were largely abolished by the non-NMDA antagonist CNQX. Immunofluorescent labeling revealed that the immunoreactivity of m opioid receptors was co-localized with synaptophysin, a presynaptic marker, in close appositions to labeled CeA neurons. These results suggest that activation of µ opioid receptors on presynaptic terminals primarily attenuates GABAergic synaptic inputs to PAG-projecting neurons in the CeA.


Key words: analgesia, brainstem, descending modulation, opioids, pain, synaptic transmission


This article has been cited by other articles:


Home page
J. Neurophysiol.Home page
P. Sah
Canonical Organization of Opioid Modulation of Nociceptive Circuits. Focus on "{micro} Opioid Receptor Activation Inhibits GABAergic Inputs to Basolateral Amygdala Neurons Through Kv1.1/Kv1.2 Channels"
J Neurophysiol, April 1, 2006; 95(4): 2029 - 2030.
[Full Text] [PDF]


Home page
J. Neurophysiol.Home page
T. F. Finnegan, S.-R. Chen, and H.-L. Pan
{micro} Opioid Receptor Activation Inhibits GABAergic Inputs to Basolateral Amygdala Neurons Through Kv1.1/1.2 Channels
J Neurophysiol, April 1, 2006; 95(4): 2032 - 2041.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.